AR057906A1 - Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. - Google Patents
Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.Info
- Publication number
- AR057906A1 AR057906A1 ARP060105057A ARP060105057A AR057906A1 AR 057906 A1 AR057906 A1 AR 057906A1 AR P060105057 A ARP060105057 A AR P060105057A AR P060105057 A ARP060105057 A AR P060105057A AR 057906 A1 AR057906 A1 AR 057906A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- atom
- alkoxy
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Un medicamento que comprende dicho derivado o una de sus sales como ingrediente activo, que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad neurodegenerativa causada por la actividad anormal de GSK3beta, tal como la enfermedad de Alzheimer. Reivindicacion 1: Un derivado de pirimidona representado por la formula (1) o una de sus sales, o uno de sus solvatos o uno de sus hidratos en la que Y representa dos átomos de H, un átomo de S, un átomo de O o alquilo C1-2 y un átomo de H; Z representa un enlace, O, N sustituido con un H o alquilo C1-3, S, metileno opcionalmente sustituido con 1 o 2 grupos elegidos entre alquilo C1-6, hidroxilo, alcoxi C1-6, alquiloC1-2 perhalogenado o un grupo amino; R1 representa un anillo de 2, 3 o 4-piridina o un anillo de 2, 4 o 5-pirimidina, estando el anillo opcionalmente sustituido con un grupo alquilo C1-6, alcoxi C1-6 o un átomo de halogeno; R2 representa un anillo bencénico o un anillo naftalénico; estando los anillos opcionalmente sustituidos con 1 a 4 sustituyentes seleccionados entre un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, un átomo de halogeno, alquilo C1-2 perhalogenado, alquilo C1-3 halogenado, hidroxilo., alcoxi C1-6 opcionalmente sustituido con un grupo cicloalquilo C3-5, alcoxi C1-2 perhalogenado, un grupo alquilsulfonilo C1-6, nitro, ciano, amino, monoalquilamino C1-6 o dialquilamino C2-12, acetoxi o aminosulfonilo; R3 representa un átomo de H, un grupo alquilo C1-6 o un átomo de halogeno; R4 representa H o alquilo C1-6; R5 representa H alquilo C1-6 opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un átomo de halogeno, un grupo fenilo, un grupo hidroxilo o alcoxi C1-6; R6 representa H, alquilo C1-6 o un átomo de halogeno; R7 representa un átomo de H o alquilo C1-6; y n representa 0 a 3; m representa 0 a 1; o representa 0 a 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05292457A EP1790649A1 (en) | 2005-11-21 | 2005-11-21 | Substituted bicyclic pyrimidone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057906A1 true AR057906A1 (es) | 2007-12-26 |
Family
ID=35659035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105057A AR057906A1 (es) | 2005-11-21 | 2006-11-17 | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8148364B2 (es) |
| EP (2) | EP1790649A1 (es) |
| JP (1) | JP5124471B2 (es) |
| KR (1) | KR20080070671A (es) |
| CN (1) | CN101312971B (es) |
| AR (1) | AR057906A1 (es) |
| AT (1) | ATE487718T1 (es) |
| BR (1) | BRPI0618752A2 (es) |
| CA (1) | CA2630360A1 (es) |
| CY (1) | CY1111125T1 (es) |
| DE (1) | DE602006018190D1 (es) |
| DK (1) | DK1957492T3 (es) |
| EA (1) | EA014918B1 (es) |
| ES (1) | ES2355756T3 (es) |
| HK (1) | HK1126204A1 (es) |
| HR (1) | HRP20100724T1 (es) |
| IL (1) | IL191213A (es) |
| MX (1) | MX2008006321A (es) |
| NZ (1) | NZ568014A (es) |
| PL (1) | PL1957492T3 (es) |
| PT (1) | PT1957492E (es) |
| RS (1) | RS51654B (es) |
| SI (1) | SI1957492T1 (es) |
| WO (1) | WO2007057790A2 (es) |
| ZA (1) | ZA200804335B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1992621A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992625A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
| EP1992620A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
| EP2085399A1 (en) | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| EP2085400A1 (en) | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | Substituted heteroarylamide oxazepinopyrimidone derivatives |
| EP2138494A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| EP2138492A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
| EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| EP2138498A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
| EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
| EP2138495A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
| JP7250686B2 (ja) * | 2017-10-06 | 2023-04-03 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019070044A1 (ja) | 2017-10-06 | 2019-04-11 | 武田薬品工業株式会社 | 複素環化合物 |
| CN109748914B (zh) * | 2018-12-29 | 2021-05-25 | 上海珂臻医药科技有限公司 | 吡啶并嘧啶类化合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU178496B (en) * | 1977-12-29 | 1982-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity |
| ATE303383T1 (de) * | 1999-12-17 | 2005-09-15 | Chiron Corp | Bizyklische inhibitoren von glycogen synthase kinase 3 |
| EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
-
2005
- 2005-11-21 EP EP05292457A patent/EP1790649A1/en not_active Withdrawn
-
2006
- 2006-11-12 ZA ZA200804335A patent/ZA200804335B/xx unknown
- 2006-11-17 AR ARP060105057A patent/AR057906A1/es not_active Application Discontinuation
- 2006-11-21 NZ NZ568014A patent/NZ568014A/en not_active IP Right Cessation
- 2006-11-21 SI SI200630901T patent/SI1957492T1/sl unknown
- 2006-11-21 AT AT06847275T patent/ATE487718T1/de active
- 2006-11-21 MX MX2008006321A patent/MX2008006321A/es active IP Right Grant
- 2006-11-21 DE DE602006018190T patent/DE602006018190D1/de active Active
- 2006-11-21 PL PL06847275T patent/PL1957492T3/pl unknown
- 2006-11-21 KR KR1020087012084A patent/KR20080070671A/ko not_active Application Discontinuation
- 2006-11-21 WO PCT/IB2006/004046 patent/WO2007057790A2/en active Application Filing
- 2006-11-21 BR BRPI0618752-8A patent/BRPI0618752A2/pt not_active IP Right Cessation
- 2006-11-21 PT PT06847275T patent/PT1957492E/pt unknown
- 2006-11-21 CN CN2006800435223A patent/CN101312971B/zh not_active Expired - Fee Related
- 2006-11-21 JP JP2008540723A patent/JP5124471B2/ja not_active Expired - Fee Related
- 2006-11-21 RS RS20110055A patent/RS51654B/en unknown
- 2006-11-21 DK DK06847275.2T patent/DK1957492T3/da active
- 2006-11-21 EA EA200801134A patent/EA014918B1/ru not_active IP Right Cessation
- 2006-11-21 ES ES06847275T patent/ES2355756T3/es active Active
- 2006-11-21 CA CA002630360A patent/CA2630360A1/en not_active Abandoned
- 2006-11-21 EP EP06847275A patent/EP1957492B1/en active Active
-
2008
- 2008-05-01 IL IL191213A patent/IL191213A/en not_active IP Right Cessation
- 2008-05-16 US US12/122,111 patent/US8148364B2/en not_active Expired - Fee Related
-
2009
- 2009-05-22 HK HK09104689.9A patent/HK1126204A1/xx not_active IP Right Cessation
-
2010
- 2010-12-27 HR HR20100724T patent/HRP20100724T1/hr unknown
-
2011
- 2011-01-21 CY CY20111100069T patent/CY1111125T1/el unknown
- 2011-08-03 US US13/197,228 patent/US20110294786A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101312971B (zh) | 2011-09-07 |
| US20110294786A1 (en) | 2011-12-01 |
| PT1957492E (pt) | 2011-01-24 |
| JP2009516676A (ja) | 2009-04-23 |
| WO2007057790A3 (en) | 2007-10-11 |
| IL191213A (en) | 2012-02-29 |
| US8148364B2 (en) | 2012-04-03 |
| CA2630360A1 (en) | 2007-05-24 |
| US20090036427A1 (en) | 2009-02-05 |
| EA014918B1 (ru) | 2011-04-29 |
| ZA200804335B (en) | 2010-05-26 |
| RS51654B (en) | 2011-10-31 |
| EP1957492A2 (en) | 2008-08-20 |
| HRP20100724T1 (hr) | 2011-02-28 |
| MX2008006321A (es) | 2009-03-23 |
| EA200801134A1 (ru) | 2009-02-27 |
| ATE487718T1 (de) | 2010-11-15 |
| HK1126204A1 (en) | 2009-08-28 |
| EP1790649A1 (en) | 2007-05-30 |
| CY1111125T1 (el) | 2015-06-11 |
| KR20080070671A (ko) | 2008-07-30 |
| JP5124471B2 (ja) | 2013-01-23 |
| DK1957492T3 (da) | 2011-02-28 |
| WO2007057790A2 (en) | 2007-05-24 |
| PL1957492T3 (pl) | 2011-04-29 |
| BRPI0618752A2 (pt) | 2011-09-27 |
| SI1957492T1 (sl) | 2011-02-28 |
| EP1957492B1 (en) | 2010-11-10 |
| CN101312971A (zh) | 2008-11-26 |
| NZ568014A (en) | 2011-07-29 |
| ES2355756T3 (es) | 2011-03-30 |
| DE602006018190D1 (de) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR043485A1 (es) | Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos | |
| AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| UY28578A1 (es) | Derivados de amida | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| CO5550436A2 (es) | Derivados de benzamida | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR072224A1 (es) | Derivados de pirimidona sustituidos | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| UY29301A1 (es) | Derivados amida | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |